Oppenheimer initiated coverage on Sera Prognostics with a new price target
$SERA
Medical Specialities
Health Care
Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00
Get the next $SERA alert in real time by email
Get the next $SERA alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $SERA
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2022 | $18.00 → $4.00 | Buy → Neutral | Citigroup |
| 11/19/2021 | $19.00 | Outperform | Oppenheimer |
| 10/15/2021 | Outperform | Cowen | |
| 8/9/2021 | Outperform | William Blair | |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $18.00 | Buy | Citigroup |
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Sera Prognostics downgraded by Citigroup with a new price target
Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously
Oppenheimer initiated coverage on Sera Prognostics with a new price target
Oppenheimer initiated coverage of Sera Prognostics with a rating of Outperform and set a new price target of $19.00
Cowen resumed coverage on Sera Prognostics
Cowen resumed coverage of Sera Prognostics with a rating of Outperform
Director Elliott Jeffrey Thomas was granted 30,534 shares (SEC Form 4)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
SEC Form 3 filed by new insider Elliott Jeffrey Thomas
3 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
Chief Information Officer Harrison Robert Gardner sold $16,116 worth of shares (3,874 units at $4.16), decreasing direct ownership by 3% to 121,757 units (SEC Form 4)
4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)
SEC Form S-8 filed by Sera Prognostics Inc.
S-8 - SERA PROGNOSTICS, INC. (0001534969) (Filer)
SEC Form 10-K filed by Sera Prognostics Inc.
10-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
Sera Prognostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the
SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD
- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors. "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognos
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PR
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025
SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Sera Prognostics to Host Virtual R&D Day on January 31
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY, Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts. During the event, Sera's man
Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.
SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)
SEC Form SC 13G filed by Sera Prognostics Inc.
SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)